(PharmaNewsWire.Com, January 07, 2017 ) Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated appetite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.
Report Highlights
The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.
High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in High-Grade Glioma (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates High-Grade Glioma (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Number of Products under Development for High-Grade Glioma, H2 2016 10 Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Investigation by Universities/Institutes, H2 2016 19 High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2016 20 High-Grade Glioma - Pipeline by AngioChem Inc, H2 2016 21 High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2016 22 High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2 2016 23 High-Grade Glioma - Pipeline by Athenex Inc, H2 2016 24
List of Figures
Number of Products under Development for High-Grade Glioma, H2 2016 10 Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Products, H2 2016 17 Assessment by Monotherapy Products, H2 2016 40 Assessment by Combination Products, H2 2016 41 Number of Products by Top 10 Targets, H2 2016 42 Number of Products by Stage and Top 10 Targets, H2 2016 42 Number of Products by Top 10 Mechanism of Actions, H2 2016 45 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 45
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
